• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例HER2阳性男性隐匿性乳腺癌伴皮肤及淋巴结转移，对曲妥珠单抗单药治疗表现出完全缓解。

A case of HER2-positive male occult breast carcinoma with skin and lymph node metastases that exhibited complete response to trastuzumab monotherapy.

作者信息

Kuninaka Kouichi, Takahashi Ryo, Nakagawa Yutaka, Nishimaki Tadashi

机构信息

Division of Digestive and General Surgery Ryukyu University Graduate School of Medicine Okinawa Japan.

出版信息

Clin Case Rep. 2017 Mar 17;5(5):591-593. doi: 10.1002/ccr3.884. eCollection 2017 May.

DOI:10.1002/ccr3.884
PMID:28469855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5412765/
Abstract

Metastatic male occult HER2-positive breast cancer can be successfully treated with trastuzumab monotherapy.

摘要

转移性男性隐匿性HER2阳性乳腺癌可用曲妥珠单抗单药治疗成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d1/5412765/81f5ce4e9bcc/CCR3-5-591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d1/5412765/26023870b5d1/CCR3-5-591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d1/5412765/81f5ce4e9bcc/CCR3-5-591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d1/5412765/26023870b5d1/CCR3-5-591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d1/5412765/81f5ce4e9bcc/CCR3-5-591-g002.jpg

相似文献

1
A case of HER2-positive male occult breast carcinoma with skin and lymph node metastases that exhibited complete response to trastuzumab monotherapy.一例HER2阳性男性隐匿性乳腺癌伴皮肤及淋巴结转移，对曲妥珠单抗单药治疗表现出完全缓解。
Clin Case Rep. 2017 Mar 17;5(5):591-593. doi: 10.1002/ccr3.884. eCollection 2017 May.
2
Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report.拉帕替尼单药治疗伴皮肤转移的隐匿性乳腺癌的疗效：病例报告
Oncol Lett. 2014 Dec;8(6):2448-2452. doi: 10.3892/ol.2014.2594. Epub 2014 Oct 9.
3
Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.原发灶不明的癌，诊断为炎性乳腺癌，采用曲妥珠单抗和长春瑞滨成功治疗。
Int J Clin Oncol. 2005 Aug;10(4):285-8. doi: 10.1007/s10147-005-0485-x.
4
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.赫敏：一项随机2期试验，比较MM - 302联合曲妥珠单抗与医生选择的化疗方案联合曲妥珠单抗，用于治疗既往接受过治疗、未使用过蒽环类药物、HER2阳性、局部晚期/转移性乳腺癌患者。
BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.
5
Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.乳腺癌细胞学确诊腋窝淋巴结转移化疗后病理完全缓解后隐匿性腋窝淋巴结转移的预后意义
Cancer. 2009 Apr 15;115(8):1605-12. doi: 10.1002/cncr.24173.
6
Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases.基于转移部位的HER2阳性乳腺癌患者疾病进展的危险因素。
Prz Menopauzalny. 2015 Sep;14(3):173-7. doi: 10.5114/pm.2015.54341. Epub 2015 Sep 30.
7
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.曲妥珠单抗单药治疗与联合治疗复发性乳腺癌：疾病进展时间和生存期
Breast Cancer. 2008;15(1):57-64. doi: 10.1007/s12282-007-0014-z.
8
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.曲妥珠单抗和拉帕替尼治疗人表皮生长因子受体 2 阳性乳腺癌脑转移女性的系统评价。
Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5.
9
Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.免疫组化HER2评分2+且荧光原位杂交检测显示HER2基因扩增的转移性乳腺癌对曲妥珠单抗单药治疗反应良好：一例报告
Breast Cancer. 2003;10(2):170-4. doi: 10.1007/BF02967645.
10
Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.新辅助治疗中接受曲妥珠单抗治疗的HER2阳性乳腺癌患者的病理完全缓解
J Coll Physicians Surg Pak. 2019 Feb;29(2):159-163. doi: 10.29271/jcpsp.2019.02.159.

引用本文的文献

1
Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report.男性隐匿性原发性乳腺癌伴小肠转移：一例报告
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.24-0089. Epub 2025 May 16.
2
Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer.曲妥珠单抗、帕妥珠单抗新辅助化疗联合改良根治性乳房切除术治疗 HER2 阳性隐匿性乳腺癌患者的病理完全缓解。
Am J Case Rep. 2024 Sep 19;25:e943936. doi: 10.12659/AJCR.943936.
3
Rare axillary cancer of unknown primary originating from the breast of a 64‑year‑old male patient: A case report and literature review.

本文引用的文献

1
A Case Report of Male Occult Breast Cancer First Manifesting as Axillary Lymph Node Metastasis With Part of Metastatic Mucinous Carcinoma.首例以腋窝淋巴结转移为首发表现且伴有部分黏液性癌转移的男性隐匿性乳腺癌病例报告
Medicine (Baltimore). 2015 Jun;94(25):e1038. doi: 10.1097/MD.0000000000001038.
2
Occult breast cancers manifesting as axillary lymph node metastasis in men: a two-case report.男性隐匿性乳腺癌表现为腋窝淋巴结转移：两例报告。
J Breast Cancer. 2012 Sep;15(3):359-63. doi: 10.4048/jbc.2012.15.3.359. Epub 2012 Sep 28.
3
Mandibular metastases as first clinical sign of an occult male breast cancer.
一名64岁男性患者源自乳腺的罕见原发性不明的腋窝癌：病例报告及文献综述
Oncol Lett. 2024 Jan 5;27(2):86. doi: 10.3892/ol.2024.14220. eCollection 2024 Feb.
下颌骨转移作为隐匿性男性乳腺癌的首发临床征象。
Int J Oral Maxillofac Surg. 2012 Oct;41(10):1211-4. doi: 10.1016/j.ijom.2012.02.018. Epub 2012 Mar 24.
4
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.人表皮生长因子受体-2 阳性乳腺癌：早期、晚期和复发性疾病的当前管理。
Curr Opin Obstet Gynecol. 2011 Feb;23(1):37-43. doi: 10.1097/gco.0b013e3283414e87.
5
Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male.口服5-氟尿嘧啶衍生物S-1对一名男性可能隐匿性乳腺癌来源的表柔比星、环磷酰胺和紫杉醇难治性皮肤转移瘤的短期疗效。
Case Rep Dermatol. 2011 Feb 23;3(1):42-8. doi: 10.1159/000325069.
6
Axillary Metastasis as the First Manifestation of Occult Breast Cancer in a Male Patient.腋窝转移作为男性隐匿性乳腺癌的首发表现
Breast Care (Basel). 2009;4(1):43-45. doi: 10.1159/000193032. Epub 2009 Feb 20.
7
A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.一例HER2阳性男性乳腺癌伴肺转移患者，对曲妥珠单抗和紫杉醇治疗反应良好。
Breast Cancer. 2009;16(2):136-40. doi: 10.1007/s12282-008-0060-1. Epub 2008 Jun 12.
8
Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer.曲妥珠单抗和阿那曲唑维持治疗对男性晚期乳腺癌的潜在益处。
Breast. 2007 Jun;16(3):323-5. doi: 10.1016/j.breast.2006.12.010. Epub 2007 Feb 9.
9
Axillary metastasis as the first manifestation of occult breast cancer in a man: a case report.男性隐匿性乳腺癌以腋窝转移为首发表现：1例病例报告
Anticancer Res. 2002 Nov-Dec;22(6B):3611-3.
10
Trastuzumab and breast cancer.
N Engl J Med. 2001 Sep 27;345(13):997-8.